KORTUC Inc. Closed Financing From AXA Japan to Accelerate Pivotal Phase II Study of Novel Radiosensitizer for Cancer Radiotherapy
Today KORTUC Inc. , a Japanese clinical-stage biopharmaceutical company focusing on the clinical and product development of a novel radiosensitizer improving the effectiveness of cancer radiotherapy (RT), announces the closing of an equity investment from AXA Japan.
- Today KORTUC Inc. , a Japanese clinical-stage biopharmaceutical company focusing on the clinical and product development of a novel radiosensitizer improving the effectiveness of cancer radiotherapy (RT), announces the closing of an equity investment from AXA Japan.
- KORTUC will use the financing to fund Research and Development activities, accelerate its Pivotal Phase II Study in the UK and pursue additional Pivotal Studies in the US.
- Currently ongoing Pivotal Phase II Study focuses on application of Kortuc radiosensitizer to locally advanced/recurrent breast cancer patients undergoing RT.